Эмэгтэйчүүдийн хорт хавдрын дунд ионкарцинома өвчний тархалт, тохиолдлыг судалсан нь

Abstract

Background: Choriocarcinoma is a rare, highly malignant neoplasm of the gestational trophoblast of the placenta, which usually presents as abnormal uterine bleeding. This tumor often demonstrates rapid hematogenous spread to multiple organs, and a good response to chemotherapy. Approximately 30% of choriocarcinoma patients exhibit metastasis at the time of diagnosis, Relapse of the disease is associated with an estimated mortality rate of 30%. In Europe and North America,about 1 in 40.000 pregnant patients and 1 in 40 patients with hydatidiform moles will develop choriocarcinoma. In Southeast Asia and Japan, 9.2 in 40000 pregnant women and 3.3 in 40 patients with hydatidiform moles will subsequently develop choriocarcinoma. Gestational choriocarcinoma follows normal pregnancy (25%), spontaneous abortion (25%), and hydatidiform mole (50%). Aim: To study the incidence, morbidity and mortality rate of choriocarcinoma. The study was conducted using a retrospective survey model. Materials and Methods: The study sample was studied at the National Cancer Center in 2011-2020 using a specially designed questionnaire using data from women diagnosed with gynecological genital cancer. The statistical analysis was performed using SPSS23 and Excel. Results: As of 2011-2020, 60 cases of choriocarcinoma were registered in Mongolia. Female genital cancer in Mongolia 2011-2020: female genital vulva, vaginal cancer 1.9% (n=102), cervical cancer 68.7% (n=3702), uterine cancer 4.9% (n=266), ovarian cancer 16.8% (n=906), respectively recorded. Therefore, choriocarcinoma accounted for 1.1% (n=60). 21.4% (n=12) of choriocarcinoma after hydatidiform mole accounted for the majority of cases.